The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma.
Elizabeth Robins Gerstner
Research Funding - Merck
Kyrre E. Emblem
No relevant relationships to disclose
Andrew S. Chi
No relevant relationships to disclose
April F. Eichler
No relevant relationships to disclose
Fred Hochberg
No relevant relationships to disclose
Jan Drappatz
No relevant relationships to disclose
Eudocia Carmen Quant
Consultant or Advisory Role - Novartis
Other Remuneration - UpToDate
Andrew David Norden
No relevant relationships to disclose
Marco C Pinho
No relevant relationships to disclose
Pavlina Polaskova
No relevant relationships to disclose
Dominique Jennings
No relevant relationships to disclose
Marek Ancukiewicz
No relevant relationships to disclose
S. Percy Ivy
No relevant relationships to disclose
Patrick Y. Wen
Consultant or Advisory Role - AstraZeneca
Rakesh K. Jain
Research Funding - MedImmune; Roche
A. Gregory Sorensen
Employment or Leadership Position - Siemens Healthcare North America
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
Tracy Batchelor
Research Funding - AstraZeneca